Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis
* Zollinger-Ellison syndrome and other hypersecretory conditions
* Part of a regimen for *Helicobacter pylori* eradication
### Adult Dosing
* **GERD (symptomatic relief, healing erosive esophagitis):** 20 mg or 40 mg orally once daily. For severe erosive esophagitis, 40 mg orally once daily may be used.
* **Maintenance of healing of erosive esophagitis:** 20 mg orally once daily.
* **Hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Maximum recommended daily dose is 240 mg.
* ***H. pylori* eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics (e.g., amoxicillin and clarithromycin or clarithromycin and metronidazole).
### Pediatric Dosing
Dosing varies by indication and age.
* **GERD (erosive esophagitis):**
* **1 to 5 years:** 10 mg orally once daily.
* **6 to 11 years:** 10 mg or 20 mg orally once daily.
* **12 years and older:** 40 mg orally once daily.
* **GERD (symptomatic):** Dosing less established, often initiated at 20 mg daily in older children.
### Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment, though caution may be advised in severe hepatic impairment.
### Contraindications
Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less common/Serious:
* **Long-term use:** Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, and potentially acute interstitial nephritis.
* **Acute interstitial nephritis**
* **Polyps:** Fundic gland polyps (adenomas)
### Key Drug Interactions
* **Drugs affected by gastric pH:** PPIs can decrease the absorption of drugs requiring an acidic environment, such as ketoconazole, itraconazole, iron salts, and vitamin B12.
* **Methotrexate:** Pantoprazole may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may increase levels of drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated; citalopram, escitalopram).
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias), vitamin B12 deficiency (e.g., anemia, neurological symptoms), and fractures with long-term use.
* Monitor magnesium levels periodically, especially in patients on long-term therapy or taking concomitant medications that lower magnesium.
* Monitor for *C. difficile* infection.
### Clinical Pearls
* Pantoprazole is generally considered less likely to inhibit CYP2C19 compared to omeprazole and esomeprazole, potentially leading to fewer drug interactions with CYP2C19 substrates like clopidogrel.
* Oral administration: granules should be mixed with applesauce or apple juice, not chewed or crushed.
* IV administration: reconstitute and further dilute. Administer as a slow infusion.
***
*This information is intended for clinical use and does not substitute for professional medical advice. Always verify current prescribing information with the official drug monograph or local protocols.*
